Skip to main content
TipRanks
Go Ultimate75% OFF

Restart Life Sciences (HN30) Stock Price & Analysis

0 Followers

HN30 Stock Chart & Stats

€0.04€0.00(0.00%)
At close: 5:30 PM GMT+1
€0.056€0.0565€0.057Nov 7Nov 26
Day’s Range
EUR 0.04 - EUR 0.04
52-Week Range
EUR 0.04 - EUR 0.08
Previous Close
EUR 0.04
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 2.58M
Enterprise Value
EUR 4.75M
Total Cash (Recent Filing)
EUR 762.36K
Total Debt (Recent Filing)
EUR 348.35K
Price to Earnings (P/E)
―
Beta
1.30
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Stabilization

The return to positive equity and relatively modest 2025 leverage represent a meaningful improvement in financial positioning. This provides more flexibility than the prior negative-equity periods, although the benefit is tempered by the company’s history of balance-sheet volatility.

Improving Cash Burn Trend

Although cash flow remains negative, the reduced magnitude of outflows versus the 2021–2022 trough indicates some improvement in cash consumption. If maintained, this trend could extend the company’s financial runway and reduce the pace at which external funding is required.

Asset Base Rebuilding

A meaningful asset base relative to prior years suggests that the company has rebuilt part of its financial resources. This can support future operations and strategic development, provided the assets contribute to a credible path toward revenue generation and improved cash economics.

Bears Say

Absent Recurring Revenue

The absence of recurring revenue is a fundamental weakness because it shows that the business has not yet demonstrated commercial traction or a dependable source of operating inflows. Without revenue generation, funding growth and validating the business model remain difficult over the medium term.

Persistent Operating Losses

Recurring negative EBIT and EBITDA indicate that core operations are not yet economically viable. This limits internal reinvestment capacity and means any future expansion must occur before operating profitability is established, increasing dependence on financing or other non-operating sources.

Continued Cash Dependence

Persistent negative operating and free cash flow shows that the company is still consuming cash rather than funding itself through operations. Continued cash burn implies reliance on external capital, which can constrain strategic flexibility and make sustained execution harder if funding needs persist.

HN30 FAQ

What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was €0.04 and its highest was €0.08 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is €2.58M.
When is Restart Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Restart Life Sciences’s earnings last quarter?
Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -€0.011 earnings per share for the quarter.
Is Restart Life Sciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 62,506,542 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Restart Life Sciences reported an EPS of -€0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in DE:HN30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology